Design Therapeutics, Inc.
As of Oct 22, 2026, Design Therapeutics is in Stage 3, the topping phase, now in week 4 (since Sep 25, 2026). It closed at $10.49, 34.2% below its 52-week high and below its 200-day average, which is rising.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is DSGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
DSGN among Biotechnology59th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …59 | DSGN | Stage 3 · wk 4 | 93 | −15.1% |
Design Therapeutics: quick answers
What stage is Design Therapeutics in?
As of Oct 22, 2026, Design Therapeutics (DSGN) is in Stage 3, the topping phase. It entered Stage 3 on Sep 25, 2026 and is in week 4. What the four stages mean
Is Design Therapeutics in an uptrend?
Its uptrend has stalled. Design Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 13.5% below its 200-day average, which is rising.
How far is Design Therapeutics from its 52-week high?
Design Therapeutics closed at $10.49 on Oct 22, 2026, 34.2% below its 52-week high of $15.94. Its 52-week low is $5.53.
How has Design Therapeutics performed over the past year?
As of Oct 22, 2026, Design Therapeutics is up 86.3% over the past year and up 15.3% so far in 2026.
Which sector and industry is Design Therapeutics in?
Design Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.